HealthEquity, Inc. $HQY Stock: Apollon Wealth Management LLC Reduces Holdings

Key Points

• Apollon Wealth Management cut its HealthEquity stake by 32.1% in the third quarter, selling 12,443 shares and retaining 26,337 shares valued at approximately $2.33 million. Institutional investors collectively own 99.55% of HQY.
• HealthEquity reported quarterly earnings of $1.24 per share, exceeding estimates by $0.05, while revenue rose 95.5% year over year to $350.73 million. The company provided fiscal 2027 EPS guidance of $4.66 to $4.73.
• HQY shares opened at $101.34, near their 52-week high of $107.62. Analysts maintain a generally positive outlook, with a consensus “Moderate Buy” rating and an average price target of $113.53.

Apollon Wealth Management LLC lessened its stake in HealthEquity, Inc. (NASDAQ:HQY - Free Report) by 32.1% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 26,337 shares of the company's stock after selling 12,443 shares during the quarter. Apollon Wealth Management LLC's holdings in HealthEquity were worth $2,330,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in HQY. Maridea Wealth Management LLC acquired a new stake in HealthEquity in the second quarter valued at approximately $2,753,000. Oxbow Advisors LLC acquired a new position in shares of HealthEquity during the first quarter worth $3,147,000. Amundi increased its holdings in shares of HealthEquity by 33.6% during the second quarter. Amundi now owns 90,327 shares of the company's stock worth $8,158,000 after buying an additional 22,735 shares in the last quarter. Deutsche Bank AG acquired a new position in shares of HealthEquity during the second quarter worth $11,986,000. Finally, Bamco Inc. NY bought a new position in shares of HealthEquity in the 2nd quarter valued at $67,776,000. Institutional investors own 99.55% of the company's stock.

HealthEquity Trading Up 0.5%

HQY opened at $101.34 on Thursday. HealthEquity, Inc. has a 1-year low of $72.76 and a 1-year high of $107.62. The company has a current ratio of 2.99, a quick ratio of 2.99 and a debt-to-equity ratio of 0.47. The company has a market cap of $8.38 billion, a P/E ratio of 36.58, a price-to-earnings-growth ratio of 1.64 and a beta of 0.24. The company has a fifty day moving average price of $95.46 and a two-hundred day moving average price of $88.91.

HealthEquity (NASDAQ:HQY - Get Free Report) last posted its quarterly earnings results on Thursday, August 27th. The company reported $1.24 earnings per share for the quarter, topping analysts' consensus estimates of $1.19 by $0.05. HealthEquity had a return on equity of 15.33% and a net margin of 17.36%. The business had revenue of $350.73 million for the quarter, compared to the consensus estimate of $349.22 million. HealthEquity's revenue for the quarter was up 95.5% on a year-over-year basis. HealthEquity has set its FY 2027 guidance at 4.660-4.730 EPS. Analysts predict that HealthEquity, Inc. will post 3.93 EPS for the current fiscal year.

Insider Transactions at HealthEquity

In related news, Director Adrian Dillon sold 7,632 shares of HealthEquity stock in a transaction on Tuesday, August 25th. The shares were sold at an average price of $104.61, for a total value of $798,383.52. Following the completion of the sale, the director owned 62,395 shares of the company's stock, valued at approximately $6,527,140.95. This trade represents a 10.90% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 1.60% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the company. BTIG Research restated a "buy" rating and set a $115.00 price objective on shares of HealthEquity in a research report on Friday, August 28th. Deutsche Bank Aktiengesellschaft increased their target price on HealthEquity from $135.00 to $142.00 and gave the company a "buy" rating in a research report on Monday, August 31st. Raymond James Financial reissued a "strong-buy" rating on shares of HealthEquity in a research note on Thursday, September 3rd. Wall Street Zen upgraded HealthEquity from a "hold" rating to a "buy" rating in a report on Saturday, October 10th. Finally, Weiss Ratings upgraded HealthEquity from a "hold (c+)" rating to a "buy (b-)" rating in a report on Friday, October 16th. One investment analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $113.53.

HealthEquity Profile

HealthEquity, Inc provides technology-enabled benefits administration and financial services that help employers and individuals manage tax-advantaged healthcare accounts. The company's offerings include health savings accounts (HSAs), flexible spending accounts (FSAs), health reimbursement arrangements (HRAs), and other consumer-directed benefits.

In addition to account administration, HealthEquity provides payment cards, investment options for eligible account holders, employee engagement tools, and digital platforms for managing healthcare benefits.

Want to see what other hedge funds are holding HQY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for HealthEquity, Inc. (NASDAQ:HQY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.